Edward Garon, MD
Hematology & Oncology · Los Angeles, CANPI 1134153745
Payments from drug & device makers
Across 589 payments — averaging $13,351 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.8M
- Novartis$2.1M
- Genentech, Inc.$540K
- Daiichi Sankyo Inc.$482K
- Mirati Therapeutics, Inc.$327K
- E.r. Squibb & Sons, L.L.C.$307K
- plus $1.3M from 27 others
Across 19 payments — averaging $1277.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$16K
- EMD Serono, Inc.$4K
- F. Hoffmann-la Roche AG$2K
- Novartis Pharma AG$1K
- GSK$985
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 186 | $2,785,668 |
| Novartis | 50 | $2,106,636 |
| Genentech, Inc. | 44 | $540,360 |
| Daiichi Sankyo Inc. | 24 | $481,718 |
| Mirati Therapeutics, Inc. | 18 | $327,128 |
| E.r. Squibb & Sons, L.L.C. | 27 | $306,654 |
| Iovance Biotherapeutics, Inc. | 27 | $297,430 |
| AstraZeneca | 21 | $286,731 |
| Eli Lilly | 11 | $281,680 |
| Regeneron | 61 | $119,044 |
| Dynavax Technologies Corporation | 13 | $92,896 |
| EMD Serono, Inc. | 16 | $88,724 |
| Bayer | 16 | $31,989 |
| F. Hoffmann-la Roche AG | 4 | $24,790 |
| GSK | 11 | $14,839 |
| AbbVie | 10 | $14,634 |
| Sanofi | 7 | $11,626 |
| Biontech SE | 4 | $11,412 |
| Gilead | 8 | $9,548 |
| Samsung Bioepis Co., Ltd. | 5 | $6,305 |
| Shionogi Inc | 1 | $4,000 |
| Boehringer Ingelheim International GmbH | 2 | $3,895 |
| Lilly USA, LLC | 1 | $3,500 |
| Seagen Inc. | 1 | $2,750 |
| Novartis Pharma AG | 4 | $2,697 |
| Eisai CO., LTD. | 1 | $1,875 |
| Pfizer | 9 | $1,650 |
| Ipsen Biopharmaceuticals, Inc | 1 | $1,500 |
| Boehringer Ingelheim | 1 | $650 |
| Sumitomo Pharma America, Inc. | 1 | $585 |
| Dr.reddy's Laboratories,inc. | 1 | $433 |
| Astrazeneca UK Limited | 2 | $124 |
| Amgen | 1 | $25 |
How this compares
$7,863,497 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Los Angeles
- David BerzLos Angeles$43.3M
- Nicholas McAndrewLos Angeles$22.9M
- Antoni RibasLos Angeles$13M
- Gary SchillerLos Angeles$11.9M
- Matthew RettigLos Angeles$8.2M
- Lasika SeneviratneLos Angeles$8.1M
- Gary BuchschacherLos Angeles$7.9M
- Gottfried KonecnyLos Angeles$7.6M
- Sven de VosLos Angeles$6.7M
- Jorge NievaLos Angeles$6.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.